Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN WESLEY PIPE

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1255341889
CMS profile
192992
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$303,788.20

159 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
BioMarin Pharmaceutical Inc. $71,415.16 32
CSL Behring $50,453.81 35
GENZYME CORPORATION $41,670.81 27
SANOFI-AVENTIS U.S. LLC $36,495.12 9
Roche Products Limited $33,637.88 8
Ultragenyx Pharmaceutical Inc. $17,627.27 5
HEMA Biologics, LLC $13,892.79 15
PFIZER INC. $12,913.25 10
Novo Nordisk Health Care AG $6,545.00 4
SANOFI US SERVICES INC. $5,538.00 1
Regeneron Pharmaceuticals, Inc. $4,974.00 3
Chugai Pharmaceutical Co., Ltd. $3,818.45 2
Genentech USA, Inc. $2,806.66 7
Samsung Bioepis Co., Ltd. $2,000.00 1

Page 3 of 4; records 101–150 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN WESLEY PIPE

NPI 1255341889 · CMS profile ID 192992

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255341889?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN WESLEY PIPE, NPI 1255341889, CMS profile ID 192992. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255341889?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). STEVEN WESLEY PIPE, NPI 1255341889, CMS profile ID 192992. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255341889?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
STEVEN WESLEY PIPE, NPI 1255341889, CMS profile ID 192992, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1255341889?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

159 matching records · $303,788.20 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 159 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 159.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
BioMarin Pharmaceutical Inc. $13.4005/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127062710 CMS
BioMarin Pharmaceutical Inc. $3,150.0005/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127062888 CMS
HEMA Biologics, LLC $154.8504/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152820981 CMS
BioMarin Pharmaceutical Inc. $84.1004/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127060960 CMS
GENZYME CORPORATION $250.0004/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621583 CMS
GENZYME CORPORATION $500.0004/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621591 CMS
GENZYME CORPORATION $250.0004/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621581 CMS
GENZYME CORPORATION $500.0004/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621585 CMS
PFIZER INC. $25.1104/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132115067 CMS
Genentech USA, Inc. $44.6204/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133117837 CMS
Regeneron Pharmaceuticals, Inc. $2,487.0004/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403757 CMS
HEMA Biologics, LLC $86.8004/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152820979 CMS
CSL Behring $219.9004/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134646471 CMS
BioMarin Pharmaceutical Inc. $674.0003/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127062708 CMS
HEMA Biologics, LLC $13.9903/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152820971 CMS
Novo Nordisk Health Care AG $3,570.0003/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096553784 CMS
HEMA Biologics, LLC $5,000.0003/23/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152820959 CMS
HEMA Biologics, LLC $132.9903/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152820963 CMS
HEMA Biologics, LLC $5.8703/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152820969 CMS
HEMA Biologics, LLC $224.7303/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152820989 CMS
HEMA Biologics, LLC $57.2603/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152820991 CMS
HEMA Biologics, LLC $116.8603/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152820997 CMS
HEMA Biologics, LLC $88.1503/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152820999 CMS
HEMA Biologics, LLC $127.5603/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152821005 CMS
CSL Behring $438.9003/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134646469 CMS
HEMA Biologics, LLC $14.5203/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152820955 CMS
Ultragenyx Pharmaceutical Inc. $412.8603/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153281481 CMS
BioMarin Pharmaceutical Inc. $4,275.0003/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127057507 CMS
PFIZER INC. $2,000.0003/08/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131629481 CMS
Regeneron Pharmaceuticals, Inc. $829.0003/08/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403753 CMS
Regeneron Pharmaceuticals, Inc. $1,658.0003/08/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403755 CMS
HEMA Biologics, LLC $869.2103/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152820975 CMS
GENZYME CORPORATION $11,468.0002/27/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621611 CMS
GENZYME CORPORATION $87.4102/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621613 CMS
GENZYME CORPORATION $25.8002/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621615 CMS
GENZYME CORPORATION $72.4602/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621617 CMS
GENZYME CORPORATION $156.9302/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621619 CMS
GENZYME CORPORATION $572.7002/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621621 CMS
GENZYME CORPORATION $355.3502/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621623 CMS
GENZYME CORPORATION $1,024.3802/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621625 CMS
BioMarin Pharmaceutical Inc. $1,800.0002/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127062486 CMS
Novo Nordisk Health Care AG $1,785.0002/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096553792 CMS
GENZYME CORPORATION $250.0002/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621553 CMS
Genentech USA, Inc. $121.6802/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133117833 CMS
CSL Behring $616.6002/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134646467 CMS
Ultragenyx Pharmaceutical Inc. $545.4901/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153281307 CMS
CSL Behring $571.6101/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134646385 CMS
GENZYME CORPORATION $12,946.9801/20/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621637 CMS
GENZYME CORPORATION $86.8001/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139621639 CMS
PFIZER INC. $750.0001/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131311634 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $151,355.49 102
PY2020 $79,386.23 32
PY2021 $111,981.61 79
PY2022 $197,180.49 130
PY2023 $226,349.98 149
PY2024 $303,788.20 159
PY2025 $251,232.42 123

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $12,977.61 19
PY2025 Principal investigator $339,468.04 96
PY2024 Recipient $20,047.93 14
PY2024 Principal investigator $301,630.34 79
PY2023 Recipient $14,674.20 12
PY2023 Principal investigator $219,416.86 44
PY2022 Recipient $5,264.27 7
PY2022 Principal investigator $254,458.25 40
PY2021 Recipient $14,471.22 8
PY2021 Principal investigator $317,985.11 38
PY2020 Recipient $32,283.78 15
PY2020 Principal investigator $350,462.29 47
PY2019 Recipient $648.26 2
PY2019 Principal investigator $437,068.33 68

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

115 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $146.97 12/30/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670438
Principal investigator 1 CSL Behring $200.56 12/24/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies No dispute reported 06/30/2026 1252670436
Principal investigator 1 CSL Behring $18.00 12/24/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670614
Principal investigator 1 CSL Behring $7,130.50 12/19/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,461.65 12/19/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138919
Recipient GENZYME CORPORATION $500.00 12/08/2025 Covered Recipient Physician ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX No dispute reported 06/30/2026 1226096416
Recipient GENZYME CORPORATION $500.00 12/06/2025 Covered Recipient Physician An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX No dispute reported 06/30/2026 1226096410
Principal investigator 1 CSL Behring $7,336.00 12/05/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670568
Recipient Regeneron Pharmaceuticals, Inc. $176.83 12/04/2025 Covered Recipient Physician A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184121507
Recipient Regeneron Pharmaceuticals, Inc. $303.43 12/04/2025 Covered Recipient Physician A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184121509
Recipient Regeneron Pharmaceuticals, Inc. $81.27 12/04/2025 Covered Recipient Physician A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184121511
Recipient Regeneron Pharmaceuticals, Inc. $39.28 12/04/2025 Covered Recipient Physician A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184121513
Recipient Regeneron Pharmaceuticals, Inc. $112.42 12/04/2025 Covered Recipient Physician A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184121515
Recipient Regeneron Pharmaceuticals, Inc. $39.28 12/04/2025 Covered Recipient Physician A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184121517
Recipient Regeneron Pharmaceuticals, Inc. $102.94 12/04/2025 Covered Recipient Physician A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184121519
Recipient Regeneron Pharmaceuticals, Inc. $138.60 12/03/2025 Covered Recipient Physician A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184121505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $732.00 11/20/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A PROSPECTIVE STUDY TO EVALUATE DISEASE CHARACTERISTICS IN HEMOPHILIA B PARTICIPANTS RECEIVING PROPHYLAXIS WITH STANDARD OF CARE FIX REPLACEMENT THERAPY No dispute reported 06/30/2026 1184138847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.00 11/20/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $645.00 11/20/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,818.15 11/20/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $542.00 11/20/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138855
Principal investigator 1 CSL Behring $600.00 11/05/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670560
Principal investigator 1 CSL Behring $750.00 11/05/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670562
Principal investigator 1 CSL Behring $812.70 11/05/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670564
Recipient GENZYME CORPORATION $250.00 11/03/2025 Covered Recipient Physician An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX No dispute reported 06/30/2026 1226096421
Recipient GENZYME CORPORATION $250.00 11/03/2025 Covered Recipient Physician ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX No dispute reported 06/30/2026 1226096427
Principal investigator 1 CSL Behring $14,639.95 10/21/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies No dispute reported 06/30/2026 1252670492
Principal investigator 1 BioMarin Pharmaceutical Inc. $600.00 10/16/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
BMN 270-401 No dispute reported 06/30/2026 1248578964
Principal investigator 1 CSL Behring $3,800.00 10/10/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670488
Principal investigator 1 CSL Behring $5,456.00 10/10/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670490
Recipient Regeneron Pharmaceuticals, Inc. $434.64 10/10/2025 Covered Recipient Physician A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184121503
Principal investigator 1 CSL Behring $74.75 10/08/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,311.44 10/03/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138641
Principal investigator 1 CSL Behring $2,521.00 10/02/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670484
Principal investigator 1 CSL Behring $2,834.90 10/02/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies No dispute reported 06/30/2026 1252670486
Principal investigator 1 Genentech, Inc. $6,060.49 09/24/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors No dispute reported 06/30/2026 1211559814
Principal investigator 1 CSL Behring $697.00 09/18/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670482
Principal investigator 1 CSL Behring $466.59 09/18/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies No dispute reported 06/30/2026 1252670610
Principal investigator 1 Genentech, Inc. $3,096.00 09/12/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors No dispute reported 06/30/2026 1211559819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,229.00 09/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $644.00 09/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138613
Principal investigator 1 CSL Behring $1,625.40 09/03/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670544
Principal investigator 1 CSL Behring $1,935.00 09/03/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670546
Principal investigator 1 CSL Behring $2,100.00 09/03/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670548
Principal investigator 1 CSL Behring $3,500.00 09/03/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670550
Principal investigator 1 CSL Behring $1,935.00 09/03/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670572
Principal investigator 1 CSL Behring $270.90 08/27/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670526
Principal investigator 1 CSL Behring $645.00 08/27/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670528
Principal investigator 1 CSL Behring $1,300.00 08/27/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670530
Principal investigator 1 CSL Behring $1,612.00 08/27/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670532
Principal investigator 1 CSL Behring $4,000.00 08/27/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670534
Principal investigator 1 CSL Behring $9,675.00 08/27/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670536
Principal investigator 1 CSL Behring $20,000.00 08/27/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670538
Principal investigator 1 CSL Behring $23,000.00 08/27/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670540
Principal investigator 1 CSL Behring $18.00 08/25/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,907.92 08/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138453
Principal investigator 1 BioMarin Pharmaceutical Inc. $1,883.00 08/06/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
BMN 270-401 No dispute reported 06/30/2026 1248578962
Principal investigator 1 CSL Behring $899.90 07/30/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies No dispute reported 06/30/2026 1252670480
Principal investigator 1 CSL Behring $542.00 07/23/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670478
Principal investigator 1 CSL Behring $19,799.00 07/14/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670476
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,913.07 07/10/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A PROSPECTIVE STUDY TO EVALUATE DISEASE CHARACTERISTICS IN HEMOPHILIA B PARTICIPANTS RECEIVING PROPHYLAXIS WITH STANDARD OF CARE FIX REPLACEMENT THERAPY No dispute reported 06/30/2026 1184138419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,600.00 07/10/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A PROSPECTIVE STUDY TO EVALUATE DISEASE CHARACTERISTICS IN HEMOPHILIA B PARTICIPANTS RECEIVING PROPHYLAXIS WITH STANDARD OF CARE FIX REPLACEMENT THERAPY No dispute reported 06/30/2026 1184138421
Principal investigator 1 CSL Behring $1,289.00 07/09/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670474
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,659.02 07/04/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138405
Principal investigator 1 CSL Behring $750.00 06/25/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670472
Principal investigator 1 CSL Behring $337.05 06/25/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670606
Principal investigator 1 Genentech, Inc. $3,839.00 06/25/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors No dispute reported 06/30/2026 1211559794
Principal investigator 1 CSL Behring $108.33 06/17/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670602
Principal investigator 1 CSL Behring $78.73 06/17/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies No dispute reported 06/30/2026 1252670604
Principal investigator 1 BioMarin Pharmaceutical Inc. $890.10 06/16/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
BMN 270-401 No dispute reported 06/30/2026 1248578960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,753.34 06/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138381
Principal investigator 1 CSL Behring $6,254.95 06/04/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies No dispute reported 06/30/2026 1252670470
Principal investigator 1 CSL Behring $1,239.00 06/03/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670468
Principal investigator 1 Genentech, Inc. $3,928.00 06/03/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors No dispute reported 06/30/2026 1211559799
Principal investigator 1 Genentech, Inc. $14,029.00 06/03/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors No dispute reported 06/30/2026 1211559803
Principal investigator 1 BioMarin Pharmaceutical Inc. $2,083.00 05/30/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
BMN 270-401 No dispute reported 06/30/2026 1248578958
Principal investigator 1 CSL Behring $1,128.46 05/28/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,782.94 05/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138371
Principal investigator 1 CSL Behring $18.00 05/27/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670598
Principal investigator 1 CSL Behring $36.00 05/23/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670596
Principal investigator 1 CSL Behring $134.00 05/22/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670594
Principal investigator 1 CSL Behring $7,446.00 05/16/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670466
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,445.20 05/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138355
Principal investigator 1 CSL Behring $2,834.90 05/14/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies No dispute reported 06/30/2026 1252670464
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,891.47 05/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138257
Recipient F. Hoffmann-La Roche AG $1,040.00 05/07/2025 Covered Recipient Physician An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors No dispute reported 06/30/2026 1211539102
Recipient F. Hoffmann-La Roche AG $534.00 05/07/2025 Covered Recipient Physician An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors No dispute reported 06/30/2026 1211539106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,870.00 05/02/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $483.00 05/02/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,458.00 05/02/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $534.53 04/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A PROSPECTIVE STUDY TO EVALUATE DISEASE CHARACTERISTICS IN HEMOPHILIA B PARTICIPANTS RECEIVING PROPHYLAXIS WITH STANDARD OF CARE FIX REPLACEMENT THERAPY No dispute reported 06/30/2026 1184138239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,088.84 04/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138241
Principal investigator 1 CSL Behring $116.00 04/24/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B No dispute reported 06/30/2026 1252670462
Principal investigator 1 CSL Behring $32.10 04/23/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,891.47 04/23/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138219
Recipient Regeneron Pharmaceuticals, Inc. $5,780.22 04/20/2025 Covered Recipient Physician HEMEB CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,615.19 04/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,752.22 04/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138197
Principal investigator 1 CSL Behring $897.00 04/02/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670458
Principal investigator 1 CSL Behring $1,289.00 04/02/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B No dispute reported 06/30/2026 1252670460
Principal investigator 1 Genentech, Inc. $3,775.00 04/01/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors No dispute reported 06/30/2026 1211559806
Recipient F. Hoffmann-La Roche AG $1,040.00 03/31/2025 Covered Recipient Physician An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors No dispute reported 06/30/2026 1211539110
Principal investigator 1 Genentech, Inc. $3,573.00 03/26/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors No dispute reported 06/30/2026 1211559810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,369.55 03/25/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30,858.81 03/19/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138175
Principal investigator 1 CSL Behring $899.90 03/14/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies No dispute reported 06/30/2026 1252670456
Principal investigator 1 CSL Behring $433.63 03/12/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies No dispute reported 06/30/2026 1252670590
Recipient Regeneron Pharmaceuticals, Inc. $721.28 02/19/2025 Covered Recipient Physician HEMEB CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121499
Principal investigator 1 BioMarin Pharmaceutical Inc. $3,409.47 02/14/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
BMN 270-401 No dispute reported 06/30/2026 1248578954
Principal investigator 1 BioMarin Pharmaceutical Inc. $5,502.00 02/14/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
BMN 270-401 No dispute reported 06/30/2026 1248578956
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,935.00 02/11/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $813.00 02/11/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $483.00 02/11/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B No dispute reported 06/30/2026 1184138007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,325.00 02/11/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A PROSPECTIVE STUDY TO EVALUATE DISEASE CHARACTERISTICS IN HEMOPHILIA B PARTICIPANTS RECEIVING PROPHYLAXIS WITH STANDARD OF CARE FIX REPLACEMENT THERAPY No dispute reported 06/30/2026 1184138009
Recipient Regeneron Pharmaceuticals, Inc. $933.42 01/10/2025 Covered Recipient Physician HEMEB CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121497